Click for original picture
Brand:Bettli
Description:Product name:Raloxifene hydrochloride Synonyms:Keoxifene CAS No.:82640-04-8 M.F.:C28H29NO4S M.W.:475.5992 Appearance:light yellow crystalline powder USES:Raloxifene will be like tamoxifen as effective,and less adverse effects
Origin:Other country Hong Kong
Model:82640-04-8
MOQ:10GramsGram/Grams
Port:Hong Kong,Shanghai,Shenzhen
Payment Terms:T/T
Supply Time:Day
Delivery Time:2017-09-18
Packaging Details:Suitable package according to your quantity
Product detail:Basic Info
| Product name | Raloxifene hydrochloride |
| Synonyms | Keoxifene |
| CAS No. | 82640-04-8 |
| M.F. | C28H29NO4S |
| M.W. | 475.5992 |
| Appearance | light yellow crystalline powder |
| USES | Raloxifene will be like tamoxifen as effective,and less adverse effects |
Raloxifene hydrochloride De
Raloxifene hydrochloride is a second-generation Selective Estrogen Receptor Modulator (SERM) of the benzothiophene family. This drug is similar in effect to tamoxifen, exhibiting estrogen receptor antagonist (blocking) properties in some tissues while acting as an estrogen receptor agonist (activator) in others.
The main point of variation between these two agents is their tissue selectivity. While raloxifene hydrochloride is a strong anti-estrogen in breast and uterine tissues, it appears to be estrogenic in bone. This allows it to protect bone density, mimicking the beneficial effects of endogenous estradiol.
In a role that was novel for an anti-estrogen, raloxifene hydrochloride was approved by the FDA for the prevention and treatment of osteoporosis in post-menopausal women. It is also being investigated for several other potential uses, including the treatment and prevention of cardiovascular disease, breast cancer, gynecomastia, prostate cancer, acromegaly, and uterine cancer.
Raloxifene hydrochloride Mechanism of Action:
Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of raloxifene are largely mediated through binding to estrogen receptors.
This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism). The agonistic or antagonistic activity of raloxiffene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promotors.
Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density and decreases fracture incidence.
Our Advantages:
1.Rich experience. Our company is a professional production leading factory in China for many years, our products have exported to Germany, Spain, UK, USA, Australia, Middle East and so many other countries , and we have got very good feedback from our customers, we had Established long friendly
relations of cooperation.
2.Great quality, purity and favorable price. Good quality is one of our secret success!
3.Safe and fast delivery.
4.Good after-sales service.
Welcome to inquiry!
